Filtered By:
Specialty: International Medicine & Public Health
Management: Budgets
Nutrition: Vitamin K
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
The Uptake of Non-Vitamin K Oral Anticoagulants in Ireland: Balancing Cost-Effectiveness Analysis and Budget Impact
For many years vitamin K antagonists (usually warfarin) were the only oral anticoagulants available to reduce stroke risk in Atrial fibrillation (AF). The non-vitamin K oral anticoagulants (NOACs) were first licensed in Ireland for stroke prevention in non-valvular AF with the approval of dabigatran etexilate in 2011. Rivaroxaban followed later that year, apixaban in 2013 and edoxaban in 2015. The National Centre for Pharmacoeconomics (NCPE) reviewed all the NOACs for cost-effectiveness prior to reimbursement approval in Ireland.
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: M Barry, S Clarke, N Geraghty Source Type: research
